The Efficacy of Tolvaptan in Congestive Heart Failure Patients with and Without Hypoalbuminemia: A Pilot Study.

BACKGROUND Heart failure (HF) with hypoalbuminemia is associated with poor response to conventional therapy. We investigated whether tolvaptan, a potent aquaretic agent, might be of benefit in HF patients with hypoalbuminemia. METHODS We prospectively enrolled 40 patients hospitalized for HF. Patients received conventional therapy including loop diuretics. We subsequently added tolvaptan in the range of 3.75-15 mg daily and it was discontinued after improvement of HF symptoms. We compared clinical and laboratory data in HF patients with and without hypoalbuminemia (defined as serum albumin <3.0 g/dL). RESULTS Tolvaptan was administered in 18 HF patients with hypoalbuminemia (Group A) and 22 HF patients without hypoalbuminemia (Group B). The mean serum albumin was 2.63 ± 0.27 and 3.46 ± 0.25 g/dL, respectively. The average urine output on tolvaptan increased significantly in both groups (1644.4 ± 797.6-3011.6 ± 1453.8 mL/day, P = 0.004; 1459 ± 612.7-2112.2 ± 724.5 mL/day, P = 0.008; respectively). In addition, we observed higher urine output on therapy in Group A than in Group B (P = 0.015). There was a moderate negative correlation between serum albumin and average urine output on tolvaptan (r = -0.42, P = 0.007). CONCLUSIONS The addition of tolvaptan to low dose loop diuretics might be an effective strategy for treatment of HF patients with hypoalbuminemia.

[1]  D. Lenihan,et al.  Loop diuretic resistance in heart failure: resistance etiology-based strategies to restoring diuretic efficacy. , 2014, Journal of cardiac failure.

[2]  A. Gray,et al.  Co-administration of furosemide with albumin for overcoming diuretic resistance in patients with hypoalbuminemia: a meta-analysis. , 2014, Journal of critical care.

[3]  K. Okita,et al.  Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double‐blind, placebo‐controlled trial , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  T. Koelling,et al.  Baseline Albumin Is Associated with Worsening Renal Function in Patients with Acute Decompensated Heart Failure Receiving Continuous Infusion Loop Diuretics , 2013, Pharmacotherapy.

[5]  Zeqi Huang,et al.  Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics. , 2013, Current drug metabolism.

[6]  T. Imamura,et al.  Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease. , 2013, Circulation journal : official journal of the Japanese Circulation Society.

[7]  R. Nation,et al.  Drug‐binding energetics of human α‐1‐acid glycoprotein assessed by isothermal titration calorimetry and molecular docking simulations , 2012, Journal of molecular recognition : JMR.

[8]  F. Czerwiec,et al.  Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. , 2012, Journal of hepatology.

[9]  S. Arques,et al.  Usefulness of serum albumin and serum total cholesterol in the prediction of hospital death in older patients with severe, acute heart failure. , 2011, Archives of cardiovascular diseases.

[10]  H. Shimokawa,et al.  Validation of mortality risk stratification models for cardiovascular disease. , 2011, The American journal of cardiology.

[11]  Pierre Ambrosi,et al.  Human serum albumin in the clinical syndrome of heart failure. , 2011, Journal of cardiac failure.

[12]  Adrian F. Hernandez,et al.  Combination of loop diuretics with thiazide-type diuretics in heart failure. , 2010, Journal of the American College of Cardiology.

[13]  M. Kawana,et al.  Acute decompensated heart failure syndromes (ATTEND) registry. A prospective observational multicenter cohort study: rationale, design, and preliminary data. , 2010, American heart journal.

[14]  A. Bagga,et al.  Randomized cross-over trial comparing albumin and frusemide infusions in nephrotic syndrome , 2009, Pediatric Nephrology.

[15]  M. Gheorghiade,et al.  Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. , 2008, Journal of the American College of Cardiology.

[16]  C. Yancy,et al.  Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). , 2007, American heart journal.

[17]  K. Swedberg,et al.  Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. , 2007, JAMA.

[18]  P. Sbragia,et al.  B-type natriuretic peptide and tissue Doppler study findings in elderly patients hospitalized for acute diastolic heart failure. , 2005, The American journal of cardiology.

[19]  L. Kritharides,et al.  Type of liver dysfunction in heart failure and its relation to the severity of tricuspid regurgitation. , 2002, The American journal of cardiology.

[20]  N. Chalasani,et al.  Effects of albumin/furosemide mixtures on responses to furosemide in hypoalbuminemic patients. , 2001, Journal of the American Society of Nephrology : JASN.

[21]  R. Vasan,et al.  Defining diastolic heart failure: a call for standardized diagnostic criteria. , 2000, Circulation.

[22]  K. Wiktorowicz,et al.  Intense acute phase response in ischemic patients. , 1999, International journal of cardiology.

[23]  W. Kannel,et al.  The natural history of congestive heart failure: the Framingham study. , 1971, The New England journal of medicine.